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To compare the efficacy of sharbat ustukhuddus and sharbat banafsha in the management of nazlamuzmin (chronic 
rhinosinusitis). Study was conducted on 60 patients, divided in two groups i.e., test group A (sharbat ustukhuddus) and test group B 
(sharbat banafsha), 30 patients in each group having various subjective and objective parameters, confirmed by comprehensive 
general, systemic examination as well as the local examination of nose and paranasal sinuses and diagnosis was confirmed on the 
basis of X-ray PNS (water’s view), which was carried out before and after the termination of drug therapy. 
The study was designed as open, randomized-comparative clinical trial. Subjects were randomly allocated from Ajmal 
Khan Tibbiya College & Hospital, either from IPD or OPD. The treatment period of test drug was six weeks. The study was 
divided into six visits (7th, 14th, 21st, 28th, 35th, 42th wks) with weekly follow up. Both test drugs were found to be effective 
on subjective as well as on objective parameters, these drugs significantly reduced sinus tenderness & opacity after 
treatment which were the main objective parameters but sharbat banafsha was superior than sharbat ustukhuddus and better 
remedy for this illness as it effectively relieved most of the clinical features of chronic sinusitis. 
Keywords. Chronic sinusitis, Sharbat banafsha, Sharbat ustukhuddus, Unani drugs 
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Sinusitis refers to acute or chronic inflammation/ 
infection of the paranasal sinuses and possibly the 
underlying bone, which may be due to allergies, polyp, 
subtle immune deficiency states and dental diseases
1,2,3,4
. 
It is almost always accompanied by concurrent nasal 
airway inflammation and is often preceded by symptoms 
of rhinitis. Thus the term chronic rhinosinusitis (CRS) is 
more accurate than rhinitis or sinusitis.
5
 
CRS is one of the most frequent otolaryngologic 
diseases encountered and affecting persons of all age 
groups. It accounts for substantial health care 
expenditure in-terms of office visit, antibiotic 
prescription filled, lost work days and missed school 
days
6
. Approximately one in eight persons are affected 
by the condition at least 35 million Americans suffer 
each year
7
. Sometimes patients often suffer significant 
morbidity or it can reduce quality of life, ability to get 
restful sleep and to do work. Despite its worldwide 
prevalence and substantial impact on the population, 
there is no satisfactory treatment. Continuous use of 
anti-allergic and anti-inflammatory drugs always leads 
to a number of hazardous side effects
1
. Unfortunately, 
sinusitis is often very frustrating and difficult to treat 
and medical failures often become surgical patients. 
Hence there is a strong need for greater understanding 
of the disease and for more effective treatment of CRS 
as well.
8 
 
In Unani literature there is no specific description 
of sinusitis but the features described by Unani 
physicians under nazlahaar and nazlabarid in various 
books corresponds with the signs and symptoms of 
acute & chronic sinusitis respectively
9
.
 
Most of the Unani physicians said that the phlegm 
or the morbid material dripping into the throat from 
the brain is known as Nazla and to the nose is known 
as Zukam
10,11,12,13,14
. These humors are formed, 
circulated and absorbed in the brain. When brain gets 
affected by extreme cold or heat, these humors are not 
absorbed and they start dripping from the anterior two 
ventricles into throat
15,16
. 
 
The signs and symptoms of nazlamuzmin include 
Nasal discharge
17,18
. Nasal congestion
17,18
 Sneezing
12,17,18
 
————— 
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Redness of face and eyes
17,19
. Burning, irritation, and 
itching in the nose, eyes and throat
12,18,19
. Mild 
headache
17,19
. Hot to touch
17,19
 excessive thirst
17,19
 
fatigue
17,19 
All Unani physicians unanimously ascertain that the 
genesis of nazla is related with extrinsic and intrinsic 
causative factors. One of these causes is su-e-mizaj (ill 
temperament) in the ghisha-e-mukhati (mucous 
membrane). The mucus membrane gets inflammed and 
produces secretions which may be raqeeq (watery) or 
ghaleez (viscous), garam (hot), laze (irritative), barid 
(cold) and benign, distasteful or tasteless according to 
causative factors
20
.
 
Holistic approach of Unani system of medicine may 
be much more beneficial in the cure of sinusitis. The 
system provides abundance of single and compound 
drugs, these drugs can be used for longer  
duration without any known side effects. Both sharbat 
ustukhuddus and sharbat banafsha are two very useful 
compound unani drugs, commonly prescribed in the 
management of chronic sinusitis. 
 
Material and methods 
 
Drugs& Dosage form 
The drugs for the trial were sharbat banafsha 
(composition in Table 1) and sharbat ustukhuddus 
(composition in Table 2) manufactured by Dawakhana 
Tibbiya College, Aligarh Muslim University. Both 
sharbat were given in the dose of 20 mL twice a day 
orally for six weeks. Patients were also advised to take 
steam inhalation twice a day. 
 
Place of Study 
The study was conducted in the department of 
Moalejat, Ajmal Khan Tibbiya College & Hospital, 
AMU, Aligarh, between January 2017 to June 2018. 
 
Study Design 
The study was designed as a randomized open 
comparative clinical trial on 60 patients. Subjects 
were randomly allocated from AKTC Hospital, either 
from IPD or OPD. 
 
Study Duration  
Duration of the study was 18 months. 
 
Duration of protocol Therapy 
The treatment period of both test drugs were six 
weeks. The study was divided into six visits (7
th
, 14
th
, 
21
st
, 28
th
, 35
th
, 42
th
 wks) with weekly follow up.  
Criteria for Selection of Subjects: 
A) Inclusion criteria: 
i. Clinically diagnosed patients of chronic sinusitis 
of not more than 5 years duration. 
ii. Patients of either sex. 
iii. Patients in the age group of 20 to 50 years. 
iv. Patients with involvement of any sinus. 
v. Those who given written consent. 
 
B) Exclusion criteria: 
i. Patients below 20 and above 50 years of age. 
ii. Pregnant & lactating mothers. 
iii. Patients who failed to follow up. 
iv. Mentally retarded person. 
v. Patients suffering from any congenital or acquired 
structural abnormality of the nasal cavity. 
vi. Any medical condition where physician feels that 
participation in the study could be detrimental to 
patient’s well-being. 
vii. Patients of diabetes mellitus. 
viii. Patients who failed to give consent. 
 
Method of assessment of the disease: 
a)  Subjective parameters: 
i. Nasal obstruction 
ii. Nasal discharge 
iii. Anosmia 
iv. Headache 
v. Facial pain 
vi. Halitosis 
vii. Earache 
Table 1 — Composition of sharbat banafsha21 
S. No Name of ingredient  scientific Name  Dose 
1 Gul-e-banafsha Viola odorata 120 g 
2 Shakarsafaid Saccharum officinarum 964 g 
 
Table 2 — Composition of sharbat ustukhuddus21 
S. No Name of 
ingredient 
Scientific Name Dose 
1 Ustukhuddus Lavandula stoechas 60 g 
2 Asl-us-soos Glycyrrhiza glabra 60 g 
3 Barg-e-Gaozaban Borago officinalis 60 g 
4 Badiyan Foeniculum vulgare 60 g 
5 Parsiaoshan Adiantum capillus veneris 60 g 
6 Tukhm-e-khatmi Althaea officinalis 60 g 
7 Tukhm-e-karafs Apium graveolens 60 g 
8 Sapistaan Cordia latifolia 50 in number 
9 Oodsaleeb Paeonia officinalis 60 g 
10 Gul-e-banafsha Viola odorata 84 g 
11 Gul-e-surkh Rosa Damascena 84 g 
12 Maveezmunaqqa Vitis vinifera 240 g 
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viii. Dental pain 
ix. Cough 
x. Fatigue. 
 
b) Objective parameters: 
i. Local examination of nose and paranasal sinuses 
ii. Transillumination Test 
iii. AEC (Absolute eosinophil count) 
iv. X- ray PNS (Water’s view) 
v. Above investigations were done before and after 
termination of drug therapy 
 
Investigations: 
Following investigations were carried out as safety 
parameters before commencement of protocol therapy 
for the exclusion of any concomitant acute and 
chronic illness. 
 
1) Haemogram 
Hb% (Sahli's method), TLC (Wintrobe's method), 
DLC (Wintrobe's method), ESR (Wintrobe's method) 
2)  Urine for routine and microscopic examination 
 
3)  Stool- for ova and cyst 
 
4) Random Blood Sugar 
 
5) Liver Function Test (LFT) 
Serum Total Bilirubin (Jendrassic & Grof method), 
SGOT-UV Kinetic (IFCC) method, SGPT-UV 
Kinetic (IFCC) method, Alkaline phosphatase (PNPP 
method 
 
6) Renal Function Test (RFT) 
Blood urea (UV method), Serum creatinine (Picrate 
method) 
 
Efficacy Assessment: 
The assessment of efficacy was based on subjective 
and objective parameters. The subjective parameters 
were assessed and local examination was done at 
every visit. Improvement or deterioration in 
symptoms was noted in the proforma and the results 
were compared. 
 
Withdrawal Criteria: 
i. Right of the trial subject to withdraw consent at 
any time during the course of the trial. 
ii. If the subject not willing to continue. 
iii. The cases in which adverse drug reaction was 
noticed. 
iv. Any acute systemic illness during the therapy. 
v. Drug intolerance. 
vi. Non-compliant with the study protocol. 
 
Documentation of adverse effect 
During the course of the study, no adverse event 
was reported by the patients and no adverse effect was 
detected during clinical examination or laboratory 
investigations. The formulation was well tolerated. 
 
Statistical analysis: 
Appropriate statistical tests were applied to analyze 
the data using Graph Pad In stat. For intra group 
comparison, paired t-test was used for qualitative 
analysis and chi square test was used for quantitative 
assessment. 
 
OBSERVATIONS AND RESULTS 
70 subjects were screened for the study as per the 
screening parameters, out of which only 60 subjects 
fulfilled the inclusion criteria and were enrolled for 
the study. The distribution of study subjects according 
to presenting symptoms is depicted in Table 
1,2,3,4,5,6,7,8,9 & 10 which shows effect of 
sharbatustukhuddus & sharbatbanafsha on various 
subjective and objective parameters before and after 
the termination of drug therapy. 
 
Discussion 
From the above clinical findings in both test groups 
A & B, the demographic data shows that maximum 
number of patients (65%) were found in the age group 
of 20-30 years, the incidence of disease was higher in 
females (63.3%) than males, higher incidence of 
disease was found among muslims (86.6%), 
unmarried patients (61.6%) were more than married 
(38.3%) patients, maximum number of patients were 
students (33.3%) followed by unskilled workers 
(21.6%), the higher incidence of chronic sinusitis was 
found in lower socioeconomic group (38.3%), 
maximum number of patients were having balghami 
(phlegmatic) mizaj (66.7%), out of 60 patients, 48.3% 
cases were found to have positive family history 
whereas , positive history of allergy was found in 
76.7% cases, history of smoking was found in 14.9% 
of the patients, previous history of dental infections 
was found in 11.7% of the patients and maxillary 
sinusitis was found to be the commonest type (29.9%) 
Table 3. Effect of drugs on subjective and objective 
parameters shows that headache was relieved in 76% 
patients of group A, and 84% patients of group B. On 
comparing both the groups the test statistic, ψ2=0.60, 
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p=0.43, shows non-significant difference between two 
groups Table 4 & Table 6. Nasal obstruction was 
relieved in 60% patients of group A while in group B 
it was relieved in 73% patients following treatment. 
On comparing both the groups test statistic, ψ2=0.7, 
p=0.71, indicates non- significant difference between 
the two groups. Nasal discharge was relieved in 78% 
and 84% patients in group A and B respectively. On  
Table 3 — Baseline characteristic / Demographic data (n=60) 
S. No CHARACTERISTIC TEST GROUP A (No of Patients) TEST GROUP B (No of Patients) TOTAL (% age) 
1 Age Group     
 20- 30 22 17 65 
 30-40 4 6 16.66 
 40-50 4 7 18.33 
2 Sex    
 Male 10 12 36.65 
 Female 20 18 63.3 
3 Marital Status    
 Unmarried 20 17 61.6 
 Married 10 13 38.33 
4 Occupation    
 Student  9 11 33.3 
 Professionals 2 3 8.33 
 Unskilled workers 7 6 21.66 
 Unemployed individuals 7 4 18.31 
 Housewife 5 6 18.33 
5 Religion    
 Muslim 27 25 86.65 
 Non- Muslim 3 5 13.3 
6 Socio-Economic Status    
 Upper 8 8 26.6 
 Middle 10 11 34.95 
 Lower 12 11 38.3 
7 Temperament    
 Sanguineous(damvi) 5 6 18.3 
 Phlegmatic ( balgami) 21 19 66.65 
 Bilious ( safravi) 4 4 13.3 
 Melancholic (saudawi) 0 1 1.65 
8 Family History    
 Present 15 14 48.3 
 Absent 15 16 51.7 
9 History of allergy    
 Present 22 24 76.7 
 Absent 8 6 23.3 
10 History of smoking    
 Present 4 5 15 
 Absent 26 25 85 
11 Dental infection    
 Present 3 4 11.7 
 Absent 27 26 88.3 
12 Site of Infection    
 Maxillary 10 8 30 
 Frontal 5 6 18.33 
 Ethmoidal 1 0 1.66 
 Ethmoidal+ Maxillary 3 4 11.66 
 Frontal+Maxillary 9 8 28.33 
 Pansinusitis 2 4 10 
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comparing both the groups test statistic, ψ2=0.32, 
p=0.56, indicates non-significant difference between 
the two groups. Anosmia/hyposmia was subsided in 
40% patients of group A and 71.4% patients of group 
B. Facial pain was relieved in 50% patients of group 
A and 66% patients of group B. On applying chi 
square test for comparing both the groups statistic, 
ψ2=1.6, p=0.20, indicates non-significant difference 
between the two groups. Halitosis was relieved in 
30% patients of group A and 40% patients in group B. 
On comparing both the groups using chi square test 
statistic, ψ2=0.26, p=0.60, indicates non-significant 
difference between the two groups. Earache was 
relieved in 37% patients of group A and 44.4% 
patients of group B. On comparing both the groups 
using chi square test statistic, ψ2=0.08, p=0.77, 
indicates non-significant difference between the two 
groups. Dental pain was relieved in 20% patients of 
group A and 28% of group B. Cough was relieved in 
81% and 91% patients in group A and B respectively. 
On comparing both the groups using chi square test 
statistic, ψ2=0.98, p=0.32, indicates non-significant 
difference between the two groups. Fatigue was 
subsided in 55% patients of group A and 76% patients 
in group B. on comparing both the groups test statistic, 
ψ2=1.8, p=0.17, indicates non-significant difference 
between the two groups Table 4 & Table 6. As far as 
tenderness over the sinuses is concerned, 85% patients 
Table 4 — Effect of Test drug A on subjective parameters 
Subjective 
Parameters 
Durationin weeks % age at 6 wks 
No. of Patients No. of patients improved 
0 1 2 3 4 5 6  0 1 2 3 4 5 6  
Headache 25 24 21 19 15 11 6 0 1 4 6 10 14 19 76 
Nasal Obstruction 15 14 12 10 8 7 6 0 1 3 5 7 8 9 60 
Nasal Discharge 23 22 20 15 13 9 5 0 1 3 8 10 14 18 78.2 
Cough 22 21 20 15 12 7 4 0 1 2 7 10 15 18 81 
Facial Pain 12 11 10 8 7 7 6 0 1 2 4 5 5 6 50 
Halitosis 10 10 9 9 8 7 7 0 0 1 1 2 3 3 30 
Earache 8 8 7 7 6 5 5 0 0 1 1 2 3 3 37 
Dental Pain 5 5 5 5 4 4 4 0 0 0 0 1 1 1 20 
Anosmia 10 10 9 7 7 6 6 0 0 1 3 3 4 4 40 
Fatigue 18 18 16 14 13 10 8 0 0 2 4 5 8 10 55 
 
Table 5 — Effect of Test drug A on objective parameters 
Objective Parameters Duration in weeks % age at  
6 wks No. of Patients No. of patients improved 
0 1 2 3 4 5 6  0 1 2 3 4 5 6 
Tenderness over affected sinus 23 21 19 16 13 9 7 0 2 4 7 10 14 16 69.5 
Translucency in affected sinus during 
transillumination test 
24 24 22 21 18 16 12 0 0 2 3 6 8 12 50 
Mucosal Edema 17 16 15 13 12 10 8 0 1 2 4 5 7 9 52.9 
Nasal Congestion 24 22 19 16 13 9 6 0 2 5 8 11 15 18 75 
Sinus Opacity 23             16 69.5 
Sinus haziness 24             16 66.6 
Table 6 — Effect of Test drug B on subjective parameters 
Subjective 
Parameters 
Duration in weeks % age at  
6 wks No. of Patients No. of patients improved 
0 1 2 3 4 5 6  0 1 2 3 4 5 6 
Headache 26 23 19 15 12 18 4 0 3 7 11 14 8 22 84.61 
Nasal Obstruction 19 17 14 12 9 8 5 0 2 5 7 10 11 14 73.68 
Nasal Discharge 26 23 19 15 11 7 4 0 3 7 11 15 19 22 84.6 
Cough 24 21 18 14 9 5 2 0 3 6 10 15 19 22 91.6 
Facial Pain 18 16 15 12 9 7 6 0 2 3 6 9 11 12 66.7 
Halitosis 15 14 12 11 10 9 9 0 1 3 4 5 6 6 40 
Earache 9 9 7 6 6 5 5 0 0 2 3 3 4 4 44.4 
Dental Pain 7 7 6 6 6 5 5 0 0 1 1 1 2 2 28 
Anosmia 7 6 5 4 3 2 2 0 1 2 3 4 5 5 71.4 
Fatigue 21 20 17 16 11 7 5 0 1 4 5 10 14 16 76 
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had tender sinuses. After 6 weeks of complete 
treatment 69% patients in group A and 82% in group B 
reported no tenderness. On comparing both the groups 
using chi square test statistic, ψ2=1.1, p=0.28, indicates 
non-significant difference between the two groups. At 
the beginning of the study transillumination test came 
out to be negative in 81.6% of the patients. After 6 
weeks of treatment transillumination test was observed 
positive in 50% of the patients in group A and 72% in 
group B. On comparing both the groups using chi 
square test statistic, ψ2=2.49, p=0.11, indicates non-
significant difference between the two groups. Before 
starting the treatment, 61.6% patients were observed as 
having nasal mucosal edema. On comparing both the 
groups using chi square test statistic, ψ2=1.13, p=0.28, 
indicates non-significant difference between the two 
groups. After six weeks of treatment in 52.9% patients 
of group A and 70% patients of group B no mucosal 
edema was observed. Nasal congestion was relieved in 
75% patients of group A and 92% patients of group B. 
On X-ray PNS (water’s view) haziness was found in 
83% of patient’s X-rays. After complete 6 week follow 
ups this haziness disappeared in 66% patients of group 
A and 76% of group B. On comparing both the groups 
using chi square test statistic, ψ2=3.16, p=0.75, 
indicates non-significant difference between the two 
groups Opacity in sinuses was disappeared in 69.5% 
patients of group A and 79% of group B after 
treatment. On comparing using chi square test, 
ψ2=0.56, p=0.45, indicates non-significant difference 
between two groups Table 5 & Table 7. 
Mean DEC in group A before treatment was 
9.53±0.23/cumm and after treatment it was 
8.43±0.21/cumm (t=3.4, p<0.001) showing significant 
difference. While in group B, it was 9.46±0.25/cumm 
and 8.13±1.07/cumm before and after treatment 
respectively (t=4.125, p=0.0001) indicating significant 
difference statistically. On comparing both the groups 
using unpaired t test test statistic (t=0.49, p=0.62) 
indicates non-significant difference between the two 
groups. (Table 8) 
Mean AEC in patients of group A before the 
treatment was 647±24.18/mm
3
, while after the 
treatment it was 528±19.47/mm
3
, test statistic (t=3.8, 
p<0.0003) shows significant difference. In group B, 
mean AEC was 691±14.0/mm
3
 before the treatment 
and 548±14.79/mm
3
 after the treatment, here the test 
statistic (t=7.9, p=0.0001) reported significant 
difference. On comparing both the groups using 
unpaired t test test statistic (t=1.13, p=0.26) indicates 
non-significant difference between the two groups. 
(Table 8) 
Non-significant difference was observed in 
haematological and biochemical parameters studied 
before and after the treatment. (Table 9 & Table 10) 
The effectiveness of Sharbat ustukhuddus in the 
management of nazlamuzmin may be attributed to the 
Muhallil (Anti-inflammatory activity) of 
Ustukhuddus
22,23,25,26
, Asl-us-soos
22,24,25,
, Badiyan
23,24,25,27
, 
Banafsha
24,26
, Karafs
24,26
, Khatmi
22,26,27,29
, Maveez 
Munaqqa
25
, Ood saleeb
23,24,25
, Parsiaoshan
22,23,25 
Mulattif (Demulcent activity)of Ustukhuddus
26,27
, 
Asl-us-soos
24,29
, Badiyan
27,29
, Banafsha
26
, Gaozaban
24
, 
Gul-e-surkh
26
, Khatmi
24,29
, Ood saleeb
25
, 
Parsioshan
22,23,24,25,26
, Sapistaan
24
. Muqawwi-e-dimagh 
(Brain Tonic) Ustukhuddus
22,23,25,29 
Maveez munaqqa
27 
Table 7 — Effect of Test drug Bon objective parameters 
Objective  
Parameters 
Duration in weeks % age at  
6 wks 
No. of Patients No. of patients improved 
0 1 2 3 4 5 6  0 1 2 3 4 5 6 
Tenderness over affected sinus 28 24 22 16 13 10 5 0 4 6 12 15 18 23 82 
Translucency in affected sinus 
during transillumination test 
25 25 22 18 14 11 7 0 0 3 7 11 14 18 72 
Mucosal Edema 20 20 18 15 11 8 6 0 0 2 5 9 12 14 70 
Nasal Congestion 28 28 24 20 13 10 2 0 0 4 18 15 18 26 92 
Sinus Opacity 24             19 79 
Sinus haziness 26             20 76.9 
Table 8 — Effect of Test Drugs A & B on Eosinophil Count 
S. No Investigations Test Group A Test Group B 
Mean ±SEM t value p value Mean ±SEM t value p value 
BT AT BT AT 
1. DEC 9.53 ± 0.238 8.43± 0.218 3.40 <0.001 9.46± 0.257 8.13± 1.074 4.12 0.0001 
2. AEC 647± 24.18 528 ± 19.47 3.8 <0.0003 691 ± 14.00 548 ± 14.79 7.99 <0.0001 
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and Munaqqi-e-dimagh (Brain Depurative properties) 
of Ustukhuddus
22,23,25,26,27,29
, Asl us soos
22,23,25
. 
Munaffis-e-balgham (Expectorant activity) 
ofUstukhuddus
28
, Asl-us-soos
23,24
, Banafsha
24
, 
Gaozaban
22,24,25
, Gul-e-surkh
24
, Khatmi
23
, 
Parsioshan
24
, Sapistaan
22,23,25
. Munzij-e-balgham 
(Concoctive of phlegm action) of Ustukhuddus
26
, 
Badiyan
22,25,29
, Asl-us soos
29
, Karafs
29
, Khatmi
22,23
, 
Ood saleeb
26
, Parsiaohan
22,23,25,27
. Mushil-e-balgham 
(Purgative for phlegm action) of Ustukhuddus
22,23,25,29
, 
Asl us soos
25
, Gul-e-surkh
25
. Dafa-e-ufoonat 
(Antiseptic activity) ofUstukhuddus
24
, Karafs
24
, Ood 
Saleeb
23
 and Dafa e sual (Anti tussive action) of Asl 
us soos
30
, Gul e surkh
31
, Khatmi
30 
 
 
The effectiveness of Sharbat Banafsha in the 
management of Nazla Muzmin may be due to the 
following actions of Banafsha which have been 
described in Unani literature i.e., Muhallil  
(Anti-inflammatory activity)
24,26,34
, Mulattif 
(Demulcent activity)
26,32,34
, Munaffis-e-balgham 
(Expectorant)
24,32,33,34,38
, Anti tussive (Dafa-e-
sual
)22,26,32,33,36,,37,38 
Mushil-e-safra (Purgative for 
bile)
26,34,35,36,38
, Muaddilsafrawa dam
26,34,35,36 
Musaffi-
e-dam (blood purifier)
22,26,32
, Musakkin-e-auja 
(Sedative)
35
, Munawwim (Hypnotic)
22,36
, Mulayyan-e-
halaqwa-seena
22
, Murattib (Homectant)
22
, Mughazzi 
(Nutritive)
36
, Muarriq (Diaphoretic)
24,32,34
, Daf-e-
humma (Antipyretic)
24,32,33,34,35
, Jazib (Absorbent)
26
, 
Muzalliq (lubricant)
26
 
The above mentioned properties present in 
Banafsha helps to reduce the sign and symptoms of 
chronic sinusitis. 
 
The complaint of nasal obstruction in most of the 
cases of warm-e- tajaweefanfmuzmin is due to 
inflammation and secretion of nasal mucosa which 
produce obstruction in nasal passage. Due to Muhallil 
(emollient)
24,26,34
, Mulattif (demulcent)
26,32,34
, 
properties of banafsha which reduce the inflammation 
and dissolve the thick secretion to make nasal passage 
clear and thus reduce nasal obstruction. 
 
Abnormalities of smell are restricted to less 
number of patients particularly in chronic infected 
cases of Warm-e- tajaweefanfmuzmin who develop 
thick, putrid and yellowish secretions, but after 
treatment revert to normal smell as soon as infected 
inflammatory condition of sinus mucosa is restored to 
normal Again it is due to Muhallil (emollient)
24,26,34
, 
Mulattif (demulcent)
26,32,34
, properties of banafsha 
which bring about changes in restoration of normal 
nasal mucosa. 
 
Headache may be due to inflammation and collection 
of hot and irritative secretions in the sinus involved. Due 
to Muhallil (emollient)
24,26,34
, Mulattif (demulcent)
26,32,34
, 
Munaffis-e balgham (Expectorant)
24,32,34
, Mushil-e-safra 
(Purgative for bile)
26,34,35,36
, Musakkin-e-auja 
(Sedative)
35
, Munawwim (Hypnotic)
22,36 
actions of 
banafsha helps to reduce inflammation and clear sinus 
secretion and thus relieve headache. 
Table 9 — Effect of Test Drugs A & B on Hematological Parameters 
S. No 
Investigations Test Group A Test Group B 
Mean±SEM t value p value Mean±SEM t value p value 
BT AT BT AT 
1 Hbgm/d 11.5±0.20 11.8±0.12 0.84 >0.05 12.1±0.35 12.3±0.30 0.49 >0.05 
2 ESR mm/hr 21.86±0.69 22.33±0.87 0.41 >0.05 25.4±1.23 24.9±1.33 0.25 >0.05 
3 TLC/cumm 6826±154.2 6720±174.2 0.45 >0.05 6690±99.0 6733±126 0.26 >0.05 
4 N/cumm 63.93±1.17 64.36±1.04 0.27 >0.05 66.5±0.97 66.3±0.77 0.16 >0.05 
5 L/cumm 29.9±1.12 30.0±1.23 0.03 >0.05 32.6±1.45 31.5±1.49 0.55 >0.05 
Table 10 — Effect of Test Drugs A & B on Biochemical Parameters 
S. No Investigations Test Group A Test Group B 
Mean±SEM t value p value Mean±SEM t value p value 
BT AT  BT AT 
1 BU mg/dL 23.5±0.74 23.4±0.79 0.07 >0.05 21.7±0.50 20.7±0.53 1.38 >0.05 
2 SC mg/dL 0.85±0.02 0.83±0.01 0.53 >0.05 0.88±0.02 0.88±0.02 0.23 >0.05 
3 SB mg/dL 0.87±0.01 0.85±0.01 0.74 >0.05 0.83±0.04 0.81±0.03 0.29 >0.05 
4 AST U/L 25.5±0.79 24.5±1.1 0.70 >0.05 26.6±1.1 25.8±0.95 0.55 >0.05 
5 ALT U/L 25.7±1.63 25.0±1.21 0.35 >0.05 27.7±1.63 27.2±1.52 0.22 >0.05 
6 SAP U/L 106.9±1.53 108.2±0.99 0.67 >0.05 114.5± 1.76 113.2±1.67 0.53 >0.05 
7 RBS mg/dL 80.1±2.17 82.0±2.05 0.60 >0.05 84.9±2.33 83.5±2.21 0.45 >0.05 
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Banafsha is also helpful in alleviating nasal 
discharge by reducing inflammation and irritation of 
mucous membrane due to Muhallil (emollient)
24,26,34
, 
Munaffis-e-balgham (Expectorant)
24,32,34
, Mushil-e-
safra (Purgative for bile)
26,34,35,36
, Muaddilsafrawa 
dam
26,34,35,36
, Mulayyan
22,26,32,34,35 
actions of banafsha. 
Tenderness over the involved sinus is a typical sign of 
warm-e- tajaweefanfmuzmin and it is the testimony of 
ongoing inflammatory pathology in the sinus mucosa. 
Tenderness comes down as soon as the inflammatory 
pathology is reversed, restoring abnormal sinus to 
normal one, properties like Musaffi-e-dam (blood 
purifier)
22,26,32
, Mulattif (demulcent)
26,32,34,
 Muhallil 
(Anti-inflammatory activity)
24,34 
Musakkin (Sedative)
35
 
properties of banafsha. 
 
Opacity in sinuses is produced by accumulation of 
abnormal inflammatory fluid. This production and 
accumulation of abnormal fluid, like tenderness is 
also a by-product of ongoing active process of chronic 
inflammation. As soon as inflammation is controlled 
by treatment, the opacity reduces itself accordingly. 
Banafsha helps to resolve the opacity of sinuses due 
to properties like Muhallil (emollient)
24,26,34 
Mulattif 
(Demulcent activity)
26,32,34
, Munaffis-e-balgham 
(Expectorant)
24,32,34
, Mushil-e-safra (Purgative for 
bile)
26,34,35,36
, Musaffi-e-dam (blood purifier)
22,26,32 
Musakkin-e-auja (Sedative)
35
 
 
Various pharmacological studies have also 
established the following properties of the 
constituents of Banafsha which may also be helpful in 
the management of Chronic Sinusitis: Phytochemical 
analysis of n‐hexane, butanol, methanol, and aqueous 
extracts of V. odorata aerial parts showed the 
presence of flavonoids, tannins, alkaloid, glycoside, 
and saponins. These metabolites are responsible for 
numerous pharmacological activities of different 
preparations. 
 
Anti-inflammatory activity:
39,41,42
 Aqueous 
extract of viola odorata contains combination of 
different essential oils (methy ester, salicylic acid, 
flavonoids, saponin, alkaloid, anthocyanin, gamma 
sitosterol, phytol, octadecanoid acid) causing good 
anti-inflammatory and antibacterial effect. 
Antimicrobial activity
39,40,41,42
: Methanol and 
ethanol extract of Viola odorata leaves showed 
significant zone of inhibition against two Gram 
positive bacteria, Bacillus subtilis, Staphylococcus 
aureus and two Gram negative bacteria Escherichia 
coli, Pseudomonas aeruginosa. Composition of 
methanol fraction of V. odorataL. leaves contain N-
Hexadecanoic acid, Pentadecanoic acid and 10- 
Undecyn-1-ol, ethy & methy ester, sitosterol, phytol, 
cyclotide reported to have antimicrobial activity. 
Anti-histaminic activity: (octadecanoic acid, 
methy ester)
42 
has property of antihistimic. Viola 
considerably inhibited the total serum level of IgE and 
cytokines such as IL-3 and IL-4. It also effectively 
decreased over response of the airways and 
eosinophilia and excessive secretion of mucus.
41
 
Antiviral activity: gamma-sitosterol, eugenol has 
the characteristic of an antiviral
42
.
 
Antifungal activity: peptides (cyclotides) including 
cycloviolacin Octadecanoic acid, methyl ester has the 
property of antifungal
41,42
. 
Expectorant & Anti tussive activity (violin, rutin) 
which is used as an expectorant and saponinused as 
liquidator, expectorant, antispasm and 
bronchodilator
39,41
. 
Analgesic Activity: Metanol and Aqueous extract 
of arial part of viola odaorata (salicylic acid, alkaloid, 
steroid, flavonoid, tannin, saponin, n- hexane, 
butanolic, methanolic
39,40,41
. 
Sedative & Pre anaesthetic: Mixture of methanol 
and chloroform has sedative and preanaesthetic
39,40
. 
Antioxidant Activity peptides (cyclotides), 
eugenol, phytol, tetradecanoic, hexadecanoic, methyl 
ester, dichlormethane. All extract of viola odorata 
established potent antioxidan
40,41,42 
Antipyretic Activity: The antipyretic effect of 
(eugenol, n-hexane fraction)of Viola odorata was 
reported
39,42
. 
Allama Mohd Kabirduudin in bayaz-e-kabir has 
described the efficacy of Sharbat Banafsha in coryza, 
cough, fever, headache and chest pain
21
. 
Viola odorata has been used traditionally in different 
forms for curing different medical conditions. Viola 
flower syrup was also suggested by traditional Persian 
healers such as Avicenna (980-1037 AD) and Haly 
Abbas (930-994 AD) for cough control and asthma
41
. 
In Iranian traditional medicine, it was known as a plant 
with cold and wet temperament and has been used in 
hot and dry temperament diseases such as fever, 
excessive thirst, and uremic pruritus. It also widely 
recommended in Iranian traditional medicine for 
pulmonary diseases such as cough, pneumonia, and 
pleurisy
41
. So, by virtue of these properties Sharbat 
Banafsha is effective in treating chronic sinusitis.
 
As far as safety parameters are concerned, the 
difference in the hematological and biochemical 
parameters studied, before and after treatment, was 
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found to be statistically insignificant in both groups. 
This signifies that Sharbat Banafsha is safe with the 
given dose.  
 
Conclusion 
The aim of the study was to compare the efficacy of 
unani drugs sharbatustukhuddus and sharbatbanafsha 
in the management of chronic rhinosinusitis and to 
provide safe, easy available, easily tolerable and cost-
effective drug. So, from this trial, we concluded that 
both test drugs were found to be effective on subjective 
as well as on objective parameters, Although no 
adverse effect of the drugs were reported, but sharbat 
banafsha is superior than sharbat ustukhuddus or better 
for this illness as it effectively relives most of the 
complaints due to chronic Sinusitis. However, authors 
recommend that more advanced studies need to be 
carried out .The study needs to be extra polated further 
on lager sample size. 
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